Ziprasidone versus other atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2009, Issue 4, 2009, Pages

  Komossa, Katja ^a   Rummel Kluge, Christine ^b   Hunger, Heike ^a   Schwarz, Sandra ^a   Bhoopathi, Paranthaman Sethupathi ^c   Kissling, Werner ^a   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Klinik und Poliklinik für Psychiatrie und Psychotherapie ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHOLESTEROL; CLOZAPINE; GLUCOSE; OLANZAPINE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SULPIRIDE; SULTOPRIDE; THIAZOLE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMENORRHEA; BODY WEIGHT GAIN; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; LIBIDO DISORDER; MOTOR DYSFUNCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; THIAZOLES;

EID: 75349101806     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006627.pub2     Document Type: Review

References (404)

1. Addington D, Pantelis C, Benattia I. Ziprasidone vs risperidone in schizophrenia: efficacy and safety in an 8-week trial. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S125.
2. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Journal of Clinical Psychiatry 2004;65(12):1624-33.
3. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Roychowdhury SM, Kane JM. Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. American Journal of Psychiatry 2005;162:1879-1887.
4. Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 2006;67(9):1397-403.
5. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of Clinical Psychopharmacology 2006;26(2):157-62.
6. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209-23.
7. Olie JP, Spina E, Benattia I. Ziprasidone vs amisulpride for negative symptoms of schizophrenia. Journal of the European College of Neuropsychopharmacology 2002;12(Suppl 3):S313.
8. Olie JP, Spina E, Murray S, Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International Clinical Psychopharmacology 2006;21(3):143-51.
9. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind 18-week trial. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. Toronto: American Psychiatric Association, 2006.
10. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S374.
11. Harvey PD, Bowie C, Loebel AD. Long-term cognitive improvement: ziprasidone versus olanzapine:. Proceeding of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA. New York: American Psychiatric Association, 2004.
12. Harvey PD, Bowie CR, Loebel A, Warrington L. Cognitive improvement and neuropsychological normalization with ziprasidone or olanzapine: Results of a 6-month study. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S294.
13. Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004;172(3):324-32.
14. Masand PS, Loebel AD. Analysis of remission in a six-month double-blind continuation study of ziprasidone versus olanzapine. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. Toronto: American Psychiatric Association, 2006.
15. Meyer J, Nasrallah H, Loebel A, Parsons B. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia. Proceedings of the Collegium Internationale Neuro-Psychopharmacologium 25th Biennial Congress; 2006 July 9-13; Chicago, Illinois. Chicago: Internationale Neuro-Psychopharmacologium, 2006.
16. Meyer JM, Loebel AD. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a six-week randomized study in patients with acute schizophrenia. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25;Toronto, Canada. Toronto: American Psychiatric Association, 2006.
17. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO, Simpson. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2004;161(10):1837-47.
18. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry 2005;162(8):1535-8.
19. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163(4):611-22.
20. Svestka J. Comparison of olanzapine versus ziprasidone in acute schizophrenia. Psychiatrie Prague 2005;9:4.
21. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8.
22. Baloescu A, Vasile D, Gheorghe MD, Grigorescu G. Side effects of atypical antipsychotics - prediction factor for compliance. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S403.
23. Hagger C, Mitchell D, Wise AL, Schulz SC. Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data. Proceedings of the10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. Vienna: Neuropsychopharmacology, 1997.
24. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 2004;24(1):62-9.
25. Harrison D, Leaderer M, Loebel A, Murray S. Ziprasidone vs. Olanzapine: change in coronary heart disease risk during a 6-week trial. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update" 2004 Nov 10-13; Florence, Italy. Florence: World Psychiatric Association, 2004.
26. Swanson JW, Swartz MS, Van Dorn RA. Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. Toronto: American Psychiatric Association, 2006.
27. Tang B, Lu Z, Zhou Z. A control study of ziprasidone vs clozapine in the treatment of refractory schizophrenia. Journal of Clinical Psychosomatic Diseases 2005;11(4):303-4.
28. Tudor C, Ungureanu D, Gheorghe MD. Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S397.
29. Uzun S, Folnegovic-Smalc V, Mimica N, Ljubin T, Makaric G, Ivezic S, Jelacic P, Vilibic M, Markan-Sosic V. Ziprasidone clinical trials conducted in Croatia. Schizophrenia Research 2002;53(3 Suppl 1):182.
30. A1281039. double blind, double-dummy multicenter, parallel group comparison of the efficacy and the tolerability of ziprasidone vs. Clozapine in schizophrenic patients who are refractory and/or intolerant to antipsychotic therapy. ClinicalStudyResults.org 2006.
31. ACTRN12610000954022. An open randomised clinical trial involving haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone in first episode never-treated psychosis. http://www.anzctr.org.au 2010.
32. Addington D, Pantelis C, Dineen M, Loebel A, Murray S, Dunn J. Ziprasidone vs risperidone in schizophrenia: 52 weeks comparison. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
33. Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie] 2009;54(1):46-54. [MEDLINE: 19175979].
34. Agid O, Siu C, Vanderburg D, Pappadopulos E, Brambilla C, Kapur S. Scoring algorithm for predicting long-term global functioning in patients with schizophrenia. Schizophrenia Research 2010;117(2-3):256-7.
35. Allison D, Loebel A, Lombardo I, Siu C. Effect of regression to the mean on drug-induced weight change. Schizophrenia Bulletin 2007;33(2):418.
36. Anon. New Antipsychotic, new benefits?. Current Drug Discovery 2002:11.
37. Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: A randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileira de Psiquiatria 2011;33(1):30-9. [MEDLINE: BIOSIS:PREV201100319442].
38. Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al.Broad effectiveness trial with aripiprazole in Europe Eu-Beta. Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany. 2005.
39. Beuzen J-N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al.Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
40. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al.Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. American Journal of Psychiatry 2005;162(10):1879-87.
41. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: Implications of the catie schizophrenia trial. Neurologic Clinics 2011;29(1):127-48.
42. Addington D. Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii. 2011.
43. Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al.Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Journal of Clinical Psychiatry 2011;72(1):75-80. [MEDLINE: 20868641].
44. Adkins DE, Khachane AN, McClay JL, Aberg K, Bukszar J, Sullivan PF, et al.Snp-based analysis of neuroactive ligand-receptor interaction pathways implicates pge2 as a novel mediator of antipsychotic treatment response: Data from the catie study. Schizophrenia Research 2012;135(1-3):200-1.
45. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology 2009;206(3):491-9.
46. Bick P, Knoesen N, Castle D. Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists. Australasian Psychiatry 2007;15(6):465-9. [MEDLINE: 17999256].
47. Caroff SN, Davis VG, Miller del D, Davis SM, Rosenheck RA, McEvoy JP, et al.Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry 2011;72(3):295-303. [MEDLINE: 20816031].
48. Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, et al.The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry 2009;31(1):1-7. [MEDLINE: 19134502].
49. Clark SL, Adkins DE, van den Oord EJCG. Analysis of efficacy and side effects in catie demonstrates drug response subgroups and potential for personalized medicine. Schizophrenia Research 2011;132(2-3):114-20.
50. Covell NH. Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia. Evidence-Based Mental Health 2009;12(1):13.
51. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al.Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 2008;105(1-3):175-87.
52. Davies A, Vardeva K, Loze JY, L'Italien GJ, Sennfalt K, Pugner K, et al.Cost-effectiveness of aripiprazole for the management of schizophrenia in the United Kingdom. Value in Health 2008;11:A119.
53. DeLisi LE, Nasrallah HA. The CATIE schizophrenia effectiveness trial. Schizophrenia Research 2005;80(1):5-6.
54. Fagiolini A, Goracci A. The long term--maximising potential for rehabilitation in patients with schizophrenia. European Neuropsychopharmacology 2007;17(Suppl 2):S123-S9.
55. Glick ID, Stekoll AH, Hays S. The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. Journal of Clinical Psychopharmacology 2011;31(1):82-5. [MEDLINE: BIOSIS:PREV201100089386].
56. Haddad PM, Dursun S. Selecting antipsychotics in schizophrenia: lessons from CATIE. Journal of Psychopharmacology 2006;20(3):332-4.
57. Heinrichs RW. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007;64(6):631-2. [MEDLINE: 17548745].
58. Heres S, Kissling W, Leucht S. Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. Evidence-Based Mental Health 2007;10(4):112. [MEDLINE: 17962661].
59. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, et al.The association between weight change and symptom reduction in the catie schizophrenia trial. Schizophrenia Research 2011;128(1-3):166-70.
60. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, et al.Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of Clinical Pharmacology 2010;1:73-80.
61. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al.Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007;64(6):633-47. [MEDLINE: 17548746].
62. Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, et al.Substance use and schizophrenia: Adverse correlates in the catie study sample. Schizophrenia Research 2011;132(2-3):177-82. [MEDLINE: 21872443].
63. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries D, Lawson T. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the catie study. Value in Health 2011;7:14.
64. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the catie study. Schizophrenia Research 2011;133(1-3):42-6.
65. Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H. Treatment response trajectories and antipsychotic medications: Examination of up to18months of treatment in the catie chronic schizophrenia trial. Schizophrenia Research 2012;137(1-3):141-6.
66. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.Dr. Lieberman and colleagues reply. American Journal of Psychiatry 2006;163(3):555-6.
67. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. Neuropsychopharmacology 2005;30(Suppl 1):S32.
68. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in canada: A cost-effectiveness analysis. Journal of evaluation in clinical practice 2010;16(4):744-55. [MEDLINE: 20545800].
69. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, et al.Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research 2008;103(1-3):104-9.
70. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al.Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry 2009;66(11):1013-22. [MEDLINE: 19640511].
71. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al.The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 2005;80(1):9-18.
72. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al.Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry 2008;193(4):279-88. [MEDLINE: 18827289].
73. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al.Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research 2005;80(1):33-43.
74. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin 2009;35(2):336-46. [MEDLINE: 18586692].
75. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry 2008;165(8):978-87. [MEDLINE: 18450928].
76. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrums 2006;11(7 Suppl 7):32-9.
77. Nasrallah HA, Meyer JM, McEvoy JP, Davis VG, Goff DC, Davis SM. Inflammatory markers in schizophrenia: comparing antipsychotic effects in the CATIE schizophrenia trial. Schizophrenia Bulletin 2009;35(Suppl 1):37.
78. NCT00014001. Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial). http://www.clinicaltrials.gov 2001.
79. Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al.The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research 2009;115(1):17-23. [MEDLINE: 19766459].
80. Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research 2010;116(2-3):118-25. [MEDLINE: 19864114].
81. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of catie data. Schizophrenia Research 2012;137(1-3):147-50.
82. Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, et al.Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research 2008;35(2):215-25. [MEDLINE: 18246429].
83. Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, et al.Second-generation antipsychotics: Reviewing the cost-effectiveness component of the catie trial. Expert Review of Pharmacoeconomics and Outcomes Research 2007;7(2):103-11. [MEDLINE: 20528436].
84. Rosenheck RA. Cost-effectiveness of atypical antipsychotics in the CATIE schizophrenia trial. Neuropsychopharmacology 2005;30(Suppl 1):S32.
85. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al.Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophrenia Research 2009;107(1):22-9. [MEDLINE: 18993031].
86. Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al.Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research 2009;113(1):12-8. [MEDLINE: 19545976].
87. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al.Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research 2005;80(1):1-8.
88. Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, et al.Longitudinal consent-related abilities among research participants with schizophrenia: Results from the catie study. Schizophrenia Research 2011;130(1-3):47-52. [MEDLINE: 21561740].
89. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, et al.Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research 2009;107(1):1-12. [MEDLINE: 19027269].
90. Sullivan P, David G. Pharmacogenetic studies in CATIE, a large randomized clinical trial for schizophrenia. American Journal of Medical Genetics 2006;141B(7):707.
91. Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, et al.Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. British Journal of Psychiatry 2008;193(1):37-43.
92. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, et al.What CATIE found: results from the schizophrenia trial. Psychiatric Services 2008;59(5):500-6.
93. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al.The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research 2008;100(1-3):39-52. [MEDLINE: 18191383].
94. Tsai H-T, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, et al.A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. American Journal of Medical Genetics 2010;153B(1):336-40. [MEDLINE: 19475583].
95. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, et al.Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the catie study. Journal of Clinical Pharmacology 2011;51(11):1587-91. [MEDLINE: WOS:000295893400010].
96. Wiste A, McGrath LM, Lee PH, Smoller JW. Genome-wide association study of smoking behavior among schizophrenics: Preliminary results. Biological Psychiatry 2011;69(9 Suppl S):250-1. [MEDLINE: BIOSIS:PREV201100354672].
97. Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB. Serological evidence of exposure to herpes simplex virus type 1 is associated with cognitive deficits in the catie schizophrenia sample. Schizophrenia Research 2011;128(1-3):61-5. [MEDLINE: BIOSIS:PREV201100413831].
98. Zhang F, Bigos K, Weinberger D. Genome-wide analysis of antipsychotic drug response in schizophrenia. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii 2011;50:135.
99. ChiCTR-TRC-10000934. Pharmacogenomic study of schizophrenia. http://www.chictr.org/ 2010.
100. Dunn J, Harrison DJ, Cheli A, Loebel A, Murray S. Ziprasidone vs olanzapine: change in CHD risk during a 6-week trial. Proceedings of the 13th Association of European Psychiatrists Congress; 2005 Apr 2-6; Munich, Germany. 2005.
101. Eng SM, Strom BL, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al.Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: the ziprasidone observational study of cardiac outcomes (ZODIAC). Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
102. Boter H. The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. http://www.controlled-trials.com 2005.
103. Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, Grp ES. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). Journal of Clinical Psychiatry 2010;71(1):58-65. [MEDLINE: 19852905].
104. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al.Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 2009;115(2-3):97-103. [MEDLINE: 19819114].
105. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al."Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)": correction. American Journal of Psychiatry 2009;166(6):731.
106. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al.Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 2009;166(6):675-82. [MEDLINE: 19369319].
107. Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al.Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). European Neuropsychopharmacology 2010;20(5):310-6.
108. Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, et al.Correlates of cognitive impairment in first episode schizophrenia: The eufest study. Schizophrenia Research 2009;115(2-3):104-14. [MEDLINE: 19822407].
109. Kahn R. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Early Intervention in Psychiatry 2008;2(Suppl 1):A24.
110. Kahn R, Boter H. EUFEST: A randomized pragmatic long-term trial in first episode schizophrenia. European Psychiatry 2005;20:S56.
111. Kahn R, Fleischhacker WW, Karayal O, Siu C, Pappadopulos E. EUFEST: the effects of first and second generation antipsychotics on metabolic and cardiovascular risk factors. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009.
112. Kahn RS. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy. 2009; Vol. 8, issue Suppl 1.
113. Kahn RS. Effectiveness of second-generation antipsychotics in first episode schizophrenia: the EUFEST study. Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy. 2009.
114. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97. [MEDLINE: 18374841].
115. Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW, et al.Sexual dysfunction in first-episode schizophrenia patients results from european first episode schizophrenia trial. Journal of Clinical Psychopharmacology 2011;31(3):274-80. [MEDLINE: BIOSIS:PREV201100315033].
116. No authorshipindicated. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder. African Journal of Psychiatry 2009;12(1):82.
117. NTR25. The european first episode schizophrenia trial (eufest): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. http://www.trialregister.nl/trialreg/index.asp 2005.
118. Rabe-Jablonska J, Pawelczyk T, Jarema M, Olajossy M, Rybakowski J. Polish patients of the eufest study after 1 year antipsychotic treatment: Drug discontinuation and metabolic syndrome parameters. European Neuropsychopharmacology 2010;20(3):S467.
119. Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang Fleischhacker W, et al.Treatment of depression in first episode of schizophrenia: Results from eufest. European Neuropsychopharmacology 2012 May 22 [Epub ahead of print].
120. Szafranski T, Jarema M, Olajossy M, Rabe-Jablons J, Rybakowski JK. Depressive symptoms in the first episode of schizophrenia - analysis of polish results of the eufest study. Schizophrenia Research 2010;117(2-3):503. [MEDLINE: ISI:000276936801329].
121. Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, et al.Efficacy of antipsychotic drugs against hostility in the european first-episode schizophrenia trial (eufest). Journal of Clinical Psychiatry 2011;72(7):955-61. [MEDLINE: 21824456].
122. Fahnestock P, Haupt D, Schweiger J, Westerhaus E, Stevens A, Flavin K, et al.Feasibility of quantifying activity energy expenditure and caloric intake by doubly-labeled water in treated patients with schizophrenia. Schizophrenia Bulletin 2007;33(2):498-9.
123. Fleischhacker WW. Safety and tolerability of first and second generation antipsychotics. Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy. 2009.
124. Geng Y-C, Geng S-X. A control study of olanzapine and ziprasidone in the treatment of adolescent schizophrenia, 2008;6(18):60-1.
125. Goldstein D. The genetics and pharmacogenetics of neurocognition in patients with schizophrenia. Schizophrenia Bulletin 2007;33(2):299.
126. Gong D. The clinical study of ziprasidone in treatment of first - episode schizophrenia. 2008;10(6):61-4.
127. Gouzoulis-Mayfrank E. Efficacy and tolerability of ziprasidone versus clozapine in the treatment of dually diagnosed (dd-) patients with schizophrenia and cannabis use disorder: a randomised study. http://www.controlled-trials.com 2006.
128. Grootens K, Veelen N, Sitskoom M, Verkes RJ, Kahn R. Effects of olanzapine and ziprasidone on cognitve outcome in recent-onset schizophrenia. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain. 2009.
129. Grootens KP, van Veelen NMJ, Sitskoorn MM, Sabbe BGC, Peuskens J, Buitelaar JK, et al.Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. European Neuropsychopharmacology 2010;20(12):907-12.
130. Grootens KP, Van Veelen NMJ, Peuskens J, Sabbe BGC, Thys E, Buitelaar JK, et al.Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: Results of an 8-week double-blind randomized controlled trial. Schizophrenia Bulletin 2011;37(2):352-61.
131. Harrison D, Mackell J, Leaderer M. Ziprasidone versus olanzapine: changes in CHD risk during a 6-week trial. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
132. Harvey PD, Cohen GM, Loebel A. Ziprasidone versus olanzapine in schizophrenia: 6-month cognitive data. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
133. Harvey PD, Galluzzo A, Sachetti E, Romeo F, Warrington L. Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double-blind comparative study. Schizophrenia Bulletin 2007;33(2):560.
134. Harvey P, Warrington L, Loebel A, Romeo F, Gorini B, Galluzzo A, et al.Cognitive effects of ziprasidone and clozapine: results from an 18-week double-blind trial. European Neuropsychopharmacology 2007;17(Suppl 4):S439.
135. Harvey PD, Warrington L, Loebel AD, Romeo F, Gorini B, Galluzzo A, et al.Cognitive effects of ziprasidone and clozapine in treatment-resistant schizophrenia: results from an 18-week double-blind trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007.
136. Harvey PD, Sacchetti E, Galluzzo A, Romeo F, Gorini B, Bilder RM, et al.A randomized double-blind comparison of ziprasidone vs clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophrenia Research 2008;105(1-3):138-43.
137. Houston JP, Kaiser CJ, Ahl J, Berg PH, Ahmed S, Carlson C, et al.A comparison of the reduction of agitation in schizophrenic patients treated with olanzapine vs. ziprasidone in a 28-week double-blind study. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
138. Jiang C. Observation of therapeutic effect of zipraside in the treatment of chronic schizophrenia, 2008;16(12):1389-90.
139. Jiang C, Wang G. The clincal study on ziprasidone and risperidone in the treatment of patients with first-onset schizophrenia Shandong Archives of Psychiatry, 2008;21(3):212-3.
140. Johnsen E, Kroken RA, Wentzel-Larsen T, Jorgensen HA. A practical, randomized comparison of the effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009.
141. Johnsen E, Kroken RA, Wentzel-Larsen T, Jorgensen HA. Effectiveness of second-generation antipsychotics: A naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 2010;10:26. [MEDLINE: 20334680].
142. Johnsen E, Kroken RA, Jorgensen HA. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone: A randomized, naturalistic study. Schizophrenia Research 2010;117(2-3):377-78. [MEDLINE: ISI:000276936801045].
143. Johnsen E, Jorgensen HA, Kroken RA, Loberg EM. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial. European Psychiatry 2011 Dec 6 [Epub ahead of print]. [MEDLINE: 22153730].
144. Kane JM, Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, et al.Primary and readjudication mortality results from zodiac, a large simple trial of ziprasidone vs. olanzapine in patients with schizophrenia. Schizophrenia Research 2010;117(2-3):183-4.
145. Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, et al.Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33(6):1217-28. [MEDLINE: 17625502].
146. Kinon BJ, Lipkovich I, Carlson C, Dunayevich E, Edwards SB. Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
147. Kjelby E, Jorgensen HA, Kroken RA, Loberg EM, Johnsen E. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: A pragmatic, randomized trial. BMC Psychiatry 2011;11(1):145. [MEDLINE: 21884578].
148. Kuwilsky A, Krumm B, Englisch S, Dressing H, Zink M. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43(6):216-20.
149. Li H. Comparison of efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia. International Medicine and Health Guidance News, 2007;13(11):77-9.
150. Li X-L, Lu X-B, Zheng S-Y. Olanzapine and ziprasidone in the treatment of schizophrenia. Shandong Archives of Psychiatry, 2007;20(3):157-8.
151. Liang S. Control study of ziprasidone and risperidone in the treatment of schizophrenia. China Pharmaceuticals, 2007;16(17):52.
152. Liu X, Jia J. Comparative study on ziprasidone and risperidone in the treatment of schizophrenia patients. Journal of the Binzhou Medical College 2008;31(2):119-20.
153. Liu W, Zhang X. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms. Chinese Journal of Health Psychology. 2008;16(2):124-5.
154. Loza B, Patejuk-Mazurek I, Polikowska M, Bednarski P, Mosiolek A, Kwasna J, et al.Crossover comparison of serum glycemia variability of intramuscular forms of antipsychotics: Aripiprazole, olanzapine and ziprasidone. European Neuropsychopharmacology 2011;21(Suppl 3):S499-500. [MEDLINE: BIOSIS:PREV201200044572].
155. Lu C. Comparative study of ziprasidone and risperidone in the treatment of schizophrenia, 2007;39(5):336-7.
156. Lu X, Wang J-L. Comparing ziprasidone and olanzapine in treatment of schizophrenia, Linchuang Jingshen Yixue Zazhi, 2008;18(5):335-6.
157. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World Journal of Biological Psychiatry 2009;10(4 Pt 3):710-8.
158. Meyer J, Loebel A, Nasrallah H. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia. Neuropsychopharmacology 2005;30(Suppl 1):S202-3.
159. Meyer J, Nasrallah H, Loebel A, Parsons B. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
160. Meyer J, Loebel A, Nasrallah H, Templeton HB. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia. Biological Psychiatry 2006;59(8 Suppl):159S.
161. Meyer J, Loebel A, Nasrallah H, Parsons B. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: Results of a 6-week randomized study in patients with acute schizophrenia. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Davos, SWITZERLAND: Elsevier Science Bv, 2006:93.
162. Murray SR, Addington DE, Pantelis C, Dineen M, Romano SJ. Ziprasidone versus risperidone in schizophrenia: a 52 weeks' comparison. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003:1.
163. Nai X-Z, Shi L, Song C-L, Zhao S-F. Comparative study on ziprasidone and risperidone in treating first episode schizophrenia. Journal of the Henan Medical College for Staff and Workers 2008;20(3):226-8.
164. NCT00077727. A study of galantamine hbr as an adjunctive treatment to atypical antipsychotic medications in outpatients with schizophrenia and associated cognitive deficits. http://www.clinicaltrials.gov 2004.
165. NCT00145444. A multicenter, double-blind, randomized trial of ziprasidone (80 - 160 mg) versus olanzapine (10 - 20 mg) in patients with recent-onset schizophrenia, schizoaffective and schizophreniform disorder. http://www.clinicaltrials.gov 2005.
166. NCT00148564. Energy homeostasis and metabolism in patients with schizophrenic disorders under treatment with atypical antipsychotics. http://www.clinicaltrials.gov 2005.
167. NCT00159770. Tolerability, safety, and efficacy of ziprasidone (80 - 160 mg/d) versus olanzapine (10 - 20 mg/d), risperidone (4 - 8 mg/d) or quetiapine (300 - 750 mg/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders - a 12-week open-label, multicenter clinical trial. http://www.clinicaltrials.gov 2005.
168. NCT00224315. Clozapine-augmentation with ziprasidone or risperidone, a randomized, prospective trial. http://www.clinicaltrials.gov 2005.
169. NCT00225498. Neurocognitive effects of ziprasidone: relationship to working memory and dopamine blockade. http://www.clinicaltrials.gov 2005.
170. NCT00239109. Ziprasidone versus olanzapine in the treatment of schizophrenia: a six months, double blind randomized, parallel group study. http://www.clinicaltrials.gov 2005.
171. NCT00283179. Efficacy and safety of aripiprazole in the treatment of acutely relapsed patients with schizophrenia or schizoaffective disorder with risperidone as an active control. http://www.clinicaltrials.gov 2006.
172. NCT00418171. An international, multicenter, large simple trial (LST) to compare the cardiovascular safety of ziprasidone and olanzapine. http://www.clinicaltrials.gov 2007.
173. NCT00515723. Glucose and lipid metabolism on antipsychotic medication. http://www.clinicaltrials.gov 2007.
174. NCT00634348. A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov 2008.
175. NCT00645372. A study to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients. http://www.clinicaltrials.gov 2008.
176. NCT00645515. A study comparing the safety and efficacy of ziprasidone and risperidone for the treatment of chronic schizophrenia. http://www.clinicaltrials.gov 2008.
177. NCT00649844. A study comparing the efficacy and tolerability of ziprasidone vs clozapine for the treatment of schizophrenia in patients who continue to have symptoms on or cannot tolerate other antipsychotic drugs. http://www.clinicaltrials.gov 2008.
178. NCT00932529. Use, effects and side-effects of second-generation antipsychotics in a naturalistic setting. http://www.clinicaltrials.gov 2009.
179. Newcomer JW, Haupt DW, Fahnestock PA, Flavin KS, Nicol GE, Schweiger JA, et al.Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009.
180. Newcomer JW, Haupt D, Fahnestock P, Flavin K, Nicol G, Schweiger J, et al.Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia. Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA. San Diego, CA: Oxford Univ Press, 2009:361-2.
181. Nie S-C, Zhang Y-C, Dai M-Z. A comparative study of ziprasidone and clozapine in treating schizophrenia. Medical Journal of Chinese People's Health, 2007;19(11):952-3.
182. Olfson M, Ascher-Svanum H, Faries DE, Marcus SC. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatric Services 2011;62(10):1138-45. [MEDLINE: 21969639].
183. Parsons B, Zhang H, Shu L, Li H, Gu N, Wang G, et al.double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
184. Pfizer. Effects of ziprasidone (80 - 160 mg/d) versus olanzapine (10-20 mg/d) on cognitive function in patients with schizophrenia or schizophrenic disorder previously treated with a typical neuroleptic drug (fluphenazine) - multicenter, randomized, double-blind (double-dummy), comparative study over 4 weeks with an open-label ziprasidone extension phase of up to one year. http://www.clinicalstudyresults.org/ 2005.
185. Pfizer. Down-titration schedules of amisulpride in patients suffering from schizophrenia or schizoaffective disorders when initiating therapy with ziprasidone: an open-label, three-months study. http://www.clinicalstudyresults.org/ 2006.
186. Pfizer. A six week, multicenter, double-blind, double-dummy, parallel, comparative study to compare the efficacy, safety and tolerability of ziprasidone with risperidone in the treatment of Chinese subjects with acute exacerbation of schizophrenia. ClinicalStudyResults.org 2007.
187. Rappard F, Meyer J, Loebel A, Nasrallah H. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):S287.
188. Ross DE. "randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder": comment. American Journal of Psychiatry 2005;162(7):1391.
189. Roychowdhury SM, Sethuraman G, Phillips GA, Enerson M, Berg PH, Breier A. Comparison of olanzapine to other atypical antipsychotics in preventing relapse in patients with schizophrenia. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update" 2004 Nov 10-13; Florence, Italy. 2004.
190. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
191. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L, et al.Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial. Biological Psychiatry 2006;59(8 Suppl):158S.
192. Sacchetti E, Romeo F, Galluzzo A, Valsecchi P, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):S274.
193. Sacchetti E, Galluzzo A, Romeo F, Gorini B, Warrington L. Comparison of ziprasidone and clozapine in subgroups of patients with treatment-resistant schizophrenia. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007.
194. Sacchetti E, Galluzzo A, Romeo F, Gorini B, Warrington L. Long-term efficacy of ziprasidone in treatment- resistant schizophrenia: results from a 1-year, open-label extension study. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007.
195. Sacchetti E. Efficacy of ziprasidone in the treatment of resistant schizophrenia (organized by Pfizer). World Psychiatry 2009;8(Suppl 1):SME4.
196. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia Research 2009;110(1-3):80-9. [MEDLINE: 19269791].
197. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study (DOI:10.1016/j.schres.2009.02.017). Schizophrenia Research 2009;113(1):112-21. [MEDLINE: 19606529].
198. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. "Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study": corrigendum. Schizophrenia Research 2009;113(1):111.
199. Samochowiec J, Tybura P, Wysiecka JP. Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009.
200. Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al.Proactive: Initial results of an rct comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8;a, Waikoloa, Hawaii. 2011:S104-S5.
201. Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al.Proactive: Initial results of an rct comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii. 2011.
202. Shang X-Z, Zhu J-S, Zeng D-Z, Cheng P, Sun Q-X, Chen K-Q. Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi 2007;17(6):392-3.
203. Shang X-Z, Zeng D-Z, Zhu J-S. Influence of ziprasidone on quality on life of patients with schizophrenia. Chinese Journal of Rehabilitation, 2008;23(1):69-70.
204. Shuai H-L. Ziprasidone versus risperidone in the treatment of schizophrenia: cost-effectiveness analysis. Evaluation and Analysis of Drug-Use in Hospital of China 2008;8(4):289-90.
205. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Correction: "randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder". American Journal of Psychiatry 2005;162(3):644.
206. Simpson GM, Loebel A, Warrington L, Yang R. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: results of a double-blind, six-week study, with a six-month, double-blind, continuation phase. In: Cummings JL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:149-63, xi.
207. Sonmez B, Vardar E, Altun GD, Abay E, Bedel D. Ziprasidone versus risperidone: comparison of clinical efficacy and cardiac, extrapyramidal, and metabolic side effects in patients with acute exacerbation of schizophrenia and schizoaffective disorders. Bulletin of Clinical Psychopharmacology 2009;19(2):101-12.
208. Sramek JJ, Cutler NR, Shiovitz T. The effect of antipsychotics on plasma lipids. Journal of Clinical Psychopharmacology 2003;23(6):679-80.
209. Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, et al.Olanzapine for psychotic conditions in the elderly. Psychiatric Annals 2000;30:191-6.
210. Strom B, Faich G, Reynolds RF, Eng SM, Kane M. Cardiac risk factors and schizophrenia: an analysis of 18, 094 patients enrolled in an international comparative trial of olanzapine and ziprasidone. Schizophrenia Bulletin 2007;33(2):462.
211. Strom BL, Faich G, Lombardo I, Reynolds RF, Eng SM, Kane JM. Cardiac risk factors and schizophrenia: an analysis of 18, 094 patients enrolled in an international comparative trial of olanzapine and ziprasidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA 2007.
212. Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, et al.The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. Journal of Clinical Psychiatry 2008;69(1):114-21. [MEDLINE: 18312045].
213. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al.The Ziprasidone Observational Study of Cardiac outcomes (ZODIAC): findings from a large simple trial of ziprasidone vs. Olanzapine in real-world use among 18154 patients with schizophrenia. Schizophrenia Research 2010;117(2-3):311.
214. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al.Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18, 154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (zodiac). American Journal of Psychiatry 2011;168(2):193-201.
215. Sun Q-X, Zeng D-Z, Chen K-Q. Clinical comparative study of ziprasidone in the treatment of schizophrenia. Shandong Archives of Psychiatry, 2007;20(3):150-1.
216. Svestka J. Comparison of olanzapine versus ziprasidone in acute schizophrenia [Olanzapin v. ziprasidon v lecbe akutnich exacerbaci schizofrennich a schizoafektivnich poruch]. Psychiatrie Prague 2005;9:4.
217. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al.Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 2007;164(3):428-36. [MEDLINE: 17329467].
218. Tao S-W, Chen Q, Yang C, Pan R-D, Pan T-W, Li L, et al.A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents. Journal of the Youjiang Medical College for Nationalities 2008;6:927-30.
219. Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-Based Mental Health 2007;10(3):76. [MEDLINE: 17652558].
220. Van Brunt DL, Namjoshi M, Xu W, Berg PH, Roychowdhury SM, Cavazzoni P, et al.Clinical efficacy and quality of life in a clinical trial comparing olanzapine and ziprasidone. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
221. Van Veelen NMJ, Grootens KP, Peuskens J, Sabbe BGC, Salden ME, Verkes RJ, et al.Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophrenia Research 2010;120(1-3):191-8.
222. Wang Y, Guo H, Liu Y. Comparative study on the influence of ziprasidone and clozapine on quality of life in schizophrenic. Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20-23; Shanghai 2007.
223. Wang G-P, Xie R, Pei G-X. Comparative study between ziprasidone and risperidone in treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi, 2008;18(1):55-6.
224. Wang X-Q, Zhou H-X, Zhang Y-L, Li G, Xie P-L. A comparison study of ziprasidone and risperidone in treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi, 2008;18(1):35-7.
225. Wang L, Guo H, Feng W. Contrast study of treating schizophrenia by ziprasidone and risperidone. Journal of Medical Forum, 2008;29(1):11-3.
226. Warrington L, Harvey PD, Galluzzo A, Sachetti E, Romeo F. Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double-blind comparative study. Neuropsychopharmacology 2006;31(Suppl 1):S243.
227. Wei Y, Wang X. A comparative study of ziprasidone and risperdone in the treatment of schizophrenia. Sichuan Mental Health, 2008;21(2):94-6.
228. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33(5):985-94. [MEDLINE: 17637612].
229. Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al.A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Current Medical Research and Opinion 2007;23(10):2313-23. [MEDLINE: 17706003].
230. Woodruff P. A phase IIIb, 12 week, muli-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone (40-80mg bid) versus olanzapine (5-20 mg od) on quality of life in the treatment of schizophrenia. National Research Register 2003.
231. Wu XL, Wang JH, Hu SH, Tao J. Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian Archives of Psychiatry 2012;22(1):7-11.
232. Yang J, Zhu G-H, Xie J. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia. Medical Journal of Chinese People's Health, 2008;20(23):2760-1.
233. Yi Q-M, Zhang B. A comparative study between ziprasidone and risperidone in the treatment of schizophrenia. Journal of the North Sichuan Medical College 2007;22(4):328-30.
234. Yue W, Zhang D. Pharmacogenomic study of schizophrenia. http://www.chictr.org/ 2010.
235. Zhang W-M. Contrast study of treating schizophrenia by ziprasidone, clozapine and risperidone. Medical Journal of Chinese People's Health, 2008;20(11):1122-4.
236. Zhang X, Zhang J. A comparative study on the efficacy of ziprasidone and risperidone in the treatment of schizophrenia. Shandong Archives of Psychiatry, 2008;21(5):367-9.
237. Zhang S-J, Wang M-J, Hu J. Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia. Medical Journal of Chinese People's Health, 2008;20(17):2002, 2004.
238. Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, et al.double-blind comparison of ziprasidone and risperidone in the treatment of chinese patients with acute exacerbation of schizophrenia. Neuropsychiatric Disease and Treatment 2011;7:77-85. [MEDLINE: 21552309].
239. Zhao L-P, Wang J-C. A comparative study between ziprasidone and clozapine in the treatment of patients with schizophrenia. Medical Journal of Chinese People's Health, 2008;20(5):403-4.
240. Zhu H. Ziprasidone and clozapine in treatment of schizophrenia. Medical Journal of Chinese People's Health, 2010;22(1):16-7.
241. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International Clinical Psychopharmacology 2007;22(6):363-70. [MEDLINE: 17917555].
242. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology 2009;23(3):305-14. [MEDLINE: 18562423].
243. Zou X-H, Zhou Y-F, He L-Y, Jin Y, Rong W. A comparative study of ziprasidone and olanzapine in schizophrenia with predominantly negative symptoms. Strait Pharmaceutical Journal 2008;20(3):87-9.
244. 30 cases of ziprasidone in combination with low-dose clozapine treatment of refractory schizophrenia. Herald of Medicine, 2009;28(7):872-4.
245. Ziprasidone, and risperidone in the treatment of schizophrenia. 2011;9(20):50-2.
246. Three kinds of atypical antipsychotic drugs on the ECG of patients with schizophrenia 2011;21(04):267-9.
247. Ziprasidone, and risperidone in the treatment of schizophrenia. 2011;9(27):124.
248. Ziprasidone and risperidone in the treatment of schizophrenia, 2010;30(4):311-2.
249. Ziprasidone and risperidone in the treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi, 2010;20(2):106-8.
250. A controlled study of domestic ziprasidone and risperidone in the treatment of schizophrenia. International Medicine and Health Guidance News.
251. Quetiapine and ziprasidone on the impact of ECG qtc.Chinese Journal of Health Psychology 2009;17(11):1302-3.
252. Ziprasidone and risperidone in the treatment of 60 female patients with schizophrenia.Medical Journal of Chinese People's Health,2008;20(23):2778, 2780.
253. Ziprasidone and risperidone in the treatment of Schizophrenia. Jilin Medical Journal 2010;31(22):3636-7.
254. Pharmacoeconomic analysis of clinical four antipsychotic treatment of schizophrenia, 2011;18(21):182-201.
255. Ziprasidone and risperidone in the treatment of schizophrenia double-blind controlled study. Shandong Archives of Psychiatry, 2009;22(1):55-6.
256. Ziprasidone and quetiapine in the treatment of schizophrenia and security,2011;20(15):75-6.
257. The treatment of schizophrenia, the efficacy and safety of ziprasidone hydrochloride, 2011;40(17):1693-4.
258. Control study observed 50 cases of the treatment of youth schizophrenia, 2008;16(2):47-9.
259. Ziprasidone and clozapine in the treatment of the negative symptoms of schizophrenia research. Modern Research of Integrated Chinese and Western Medicine.
260. Ziprasidone and risperidone in the treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi 2009;19(3):190-1.
261. Ziprasidone and aripiprazole the efficacy and safety of the treatment of schizophrenia, 2010;11(10):17-20.
262. Ziprasidone for schizophrenia and the effect of quality of life. Occupation and Health 2009;25(19):2109-11.
263. Efficacy and adverse reactions of ziprasidone in 30 female patients with schizophrenia. Chinese Journal of New Drugs and Clinical Remedies, 2009;28(5):360-3.
264. Ziprasidone and risperidone in the treatment of schizophrenia analysis, 2011;34(04):16-7.
265. Ziprasidone and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health, 2008;20(11):1141-2.
266. Ziprasidone given with Risperdal in the treatment of schizophrenia. Aerospace Medicine 2010;21(3):350.
267. 30 cases of ziprasidone on the quality of life of patients with schizophrenia. China Pharmaceuticals, 2009;18(21):64-5.
268. Ziprasidone and risperidone in the treatment of women with schizophrenia. Jilin Medical Journal 2010;31(31):5556-7.
269. Ziprasidone and clozapine in the treatment of schizophrenia control study, 2009;3(17):10-12.
270. Risperidone and ziprasidone on cognitive function in patients with schizophrenia, Hebei Medical Journal 2008;30(10):1505-6.
271. Ziprasidone and risperidone on prolactin in patients with schizophrenia and body mass, blood glucose, blood lipid. Shandong Archives of Psychiatry, 2010;23(1):7-9.
272. Domestic ziprasidone treatment of schizophrenia clinical observation, 2007;45(4):61-2.
273. Ziprasidone and clozapine in the treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi, 2010;20(2):119-20.
274. Ziprasidone and clozapine in the treatment of schizophrenia with negative symptoms associated control study. Medical Journal of Chinese People's Health, 2010;22(5):568-9.
275. Change-control study of ziprasidone and risperidone-induced weight and metabolic indicators, 2010;22(22):2840-75.
276. Control study of ziprasidone and risperdone in the treatment of schizophrenia,2009;12(13):31-3.
277. Ziprasidone treatment of schizophrenia with depressive symptoms were observed. Linchuang Jingshen Yixue Zazhi, 2010;20(1):44-5.
278. Ziprasidone and clozapine in the treatment of refractory schizophrenia. Medical Journal of Chinese People's Health, 2010;22(5):532-3.
279. Ziprasidone treatment of simple type schizophrenia. Linchuang Jingshen Yixue Zazhi, 2009;19(5):320-1.
280. Efficacy and safety of ziprasidone treatment of schizophrenia with acute exacerbation, 2010;19(22):2076-89.
281. Ziprasidone clinical study of treatment of schizophrenia, 2010;21:125.
282. Comparative analysis of ziprasidone risperidone in the treatment of female schizophrenia. Sichuan Mental Health, 2009;22(3):168-70.
283. Ziprasidone and olanzapine schizophrenia, 2010;8(3):98-9.
284. A randomized, double blind, double dummy parallel controlled study schizophrenia treated with ziprasidone tablets and risperidone orally disintegrating tablets, Chinese Journal of Rehabilitation Theory and Practice, 2009;15(6):556-8.
285. Chinese source, Ziprasidone and risperidone in the treatment of schizophrenia.Shandong Archives of Psychiatry, 2010;23(2):87-9.
286. Chinese source, Risperidone sustained release tablets and the ziprasidone treatment of schizophrenia. 2011;21(03):174-6.
287. Chinese source, Ziprasidone and quetiapine in the treatment of women with schizophrenia. Medical Journal of Chinese People's Health, 2010;22(15):1942-3.
288. Chinese source, Aripiprazole and ziprasidone in patients with schizophrenia glucose, lipids 2010;7(06):330-4.
289. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia, Medical Information 2010;8:2196-7.
290. Chinese source. Ziprasidone and clozapine in the treatment of schizophrenia, 2010;22(22):2841-2.
291. Chinese source. Ziprasidone and clozapine in patients with first-episode schizophrenia Comparison of the effects of ECG, Medical Journal of Chinese People's Health, 2010;22(15):1924-5.
292. Chinese source. Ziprasidone and risperidone in the treatment of senile schizophrenia. Acta Medicinae Sinica, 2008;21(3):440-2.
293. Chinese source. Ziprasidone and olanzapine clinical control study of schizophrenia, Medical Journal of Chinese People's Health,2010;22(11):1358-9.
294. Chinese source. Ziprasidone treatment of schizophrenia, randomized, double-blind controlled study, 2010;20(06):404-5.
295. Chinese source. Ziprasidone merged observation and care of small doses of clozapine treatment of refractory schizophrenia, 2011;9(07):98-9.
296. Chinese source. Ziprasidone and risperidone in the treatment of chronic schizophrenia. Medical Journal of Chinese People's Health, 2008;20(17):2020-1.
297. Chinese source. Three kinds of antipsychotic drugs on glucose metabolism in patients with schizophrenia, 2009;15(24):1-2.
298. Chinese source. Ziprasidone and clozapine in the treatment of schizophrenia, 2009;44(2):151-2.
299. Chinese source. Controlled study of aripiprazole and ziprasidone treatment of schizophrenia, 2011;9(25):242-3.
300. Chinese source. Ziprasidone and risperidone in the treatment of female control study of schizophrenia, Chinese Journal of Health Psychology, 2009;17(10):1156-8.
301. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia control study. Herald of Medicine, 2008;27(10):1197-8.
302. Chinese source. et al.Association study of four kinds of antipsychotics and glucose metabolism in patients with schizophrenia and glycosylated hemoglobin, 2010;20(18):2816-20.
303. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia control study. Medical Journal of Chinese People's Health,2008;20(5):409-10.
304. Chinese source. Comparison of health economics ziprasidone, clozapine treatment. Linchuang Jingshen Yixue Zazhi, 2009;19(2):97-8.
305. Chinese source. Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia, 2011;23(14):1708-24.
306. Chinese source. Ziprasidone and clozapine in the treatment of female schizophrenia. Journal of the Hainan Medical College 2010;16(6):771-3.
307. Chinese source. Ziprasidone social function in patients with schizophrenia and quality of life. Chinese Journal of Rehabilitation, 2010;25(2):156-8.
308. Chinese source. 80 controls were observed ziprasidone and risperidone in the treatment of schizophrenia, 2010;22(23):3042-4.
309. Chinese source. Controlled study of ziprasidone and risperidone in the treatment of women with schizophrenia, 2011;8(04):44-6.
310. Chinese source. Controlled clinical studies of ziprasidone and clozapine in the treatment of schizophrenia. Guangxi Medical Journal 2008;30(3):348-50.
311. Chinese source. Ziprasidone impact on the quality of life in patients with schizophrenia, 2008;6(13):22-3.
312. Chinese source. Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia, 2011;8(01):9-13.
313. Chinese source. Comparison of the effects of ziprasidone and clozapine, risperidone on lipid metabolism in patients with schizophrenia, 2011;14(12):1-3.
314. Chinese source. Ziprasidone treatment of schizophrenia with predominantly negative symptoms. Linchuang Jingshen Yixue Zazhi, 2008;18(3):206-7.
315. Chinese source. Efficacy of ziprasidone treatment of schizophrenia and quality of life 2009;4(23):156-7.
316. Chinese source. Ziprasidone and risperidone in the treatment of women with schizophrenia, 2010;8(1):26-7.
317. Chinese source. Ziprasidone and clozapine on cognitive function in patients with schizophrenia, 2010;5(36):5-6.
318. Chinese source. Aripiprazole and ziprasidone, the prevalence of metabolic syndrome in patients with schizophrenia, 2011;6:2570-1.
319. Chinese source. Effective control study of ziprasidone and risperidone in first episode schizophrenia, 2010;22(23):2993-4.
320. Chinese source. Ziprasidone and aripiprazole in the treatment of schizophrenia, 2009;41(3):199-200.
321. Chinese source. Three kinds of atypical antipsychotic drugs on lipid metabolism in patients with schizophrenia, 2010;8(17):8-10.
322. Chinese source. Ziprasidone and risperidone in the treatment of Schizophrenia. Medical Journal of Chinese People's Health, 2010;22(5):573-5.
323. Chinese source. Ziprasidone and clozapine on ECG, 2010;22(21):2714-18.
324. Chinese source. Ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms, Journal of the Xianning Medical College, 2009;23(2):106-8.
325. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia in the clinical control study, 2009;3(14):157.
326. Chinese source. Ziprasidone and quetiapine in the treatment of senile schizophrenia. Journal of Military Surgeon in Southwest China 2009;11(5):843-5.
327. Chinese source. Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia, 2011;18(20):71-2.
328. Chinese source. Ziprasidone treatment of low dose clozapine in refractory schizophrenia 33 patients. Zhejiang Practical Medicine 2010;15(1):43-5.
329. Chinese source. Ziprasidone and quetiapine treatment episode schizophrenia. Medical Journal of Chinese People's Health, 2008;20(12):1275, 1380.
330. Chinese source. Ziprasidone and risperidone in the treatment of female patients with schizophrenia control study. Modern Diagnosis and Treatment 2010;2:77-8.
331. Chinese source. Ziprasidone in the treatment of first diagnosis of schizophrenia. Medical Journal of Chinese People's Health, 2007;19(12):1061.
332. Chinese source. Ziprasidone and risperidone on treatment of schizophrenia. China Pharmacist 2009;12(3):363-4.
333. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi, 2009;3:190-1.
334. Chinese source. Ziprasidone, and risperidone in the treatment of adolescent schizophrenia-control study, 2010;6(10):123-4.
335. Chinese source. Ziprasidone and clozapine treatment of schizophrenia. Medical Journal of Chinese People's Health, 2008;20(23):2788, 2793.
336. Chinese source. The comparative investigation between ziprasidone and risperidone in the treatment of schizophrenia in children. 2009;36(3):137-9.
337. Chinese source. Ziprasidone treatment of schizophrenia clinical analysis of 65 cases. Medical Journal of Chinese People's Health, 2010;22(11):1380-1.
338. Chinese source. Controlled study of ziprasidone and risperidone in the treatment of schizophrenia, 2010;12:3715-6.
339. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health, 2010;22(5):559-61.
340. Chinese source. Ziprasidone and risperidone in the treatment of schizophrenia. Journal of Medical Forum, 2009;30(24):72-4.
341. Chinese source. Ziprasidone and aripiprazole improve control study of first episode schizophrenia and social functions, 2011;24(07):4219-20.
342. Chinese source. Ziprasidone and aripiprazole treatment of first episode of schizophrenia, 2011;15(10):929-30.
343. Chinese source. Ziprasidone and risperidone in the treatment of female schizophrenia. Modern Research of Integrated Chinese and Western Medicine, 2008;17(20):3110-1.
344. Chinese source. Ziprasidone risperdal in the treatment of schizophrenia, 2008;8:46.
345. Chinese source. Ziprasidone and olanzapine in schizophrenia. Journal of the Guangdong Medical College 2009;27(4):434-5.
346. Chinese source. Ziprasidone treatment of female patients with schizophrenia, efficacy and quality of life impact study, 2011;41(05):11-3.
347. Chinese source. Ziprasidone and quetiapine treatment 30 patients in each episode schizophrenia, 2009;4(4):577-9.
348. Chinese source. Ziprasidone Efficacy of first-episode schizophrenia treatment, 2010;8(15):10-11.
349. Chinese source. Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia, 2011;9(18):111-3.
350. Chinese source. Ziprasidone substitution of female patients with schizophrenia. Risperidone study of the Effect of prolactin. Nei Moivgol Medical Journal 2010;42(1):38-9.
351. Chinese source. Control study of ziprasidone and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health, 2008;20(12):1273, 1301.
352. Chinese source. Clozapine with ziprasidone capsules with a single controlled clinical study the treatment of schizophrenia with clozapine. 2011;9(24):56-7.
353. Chinese source. The comparation of effects and security of ziprasidone and quetiapine in the treatment of schizophrenia,2009;31(3):163-6.
354. Chinese source. Ziprasidone efficacy of cognitive function in patients with chronic schizophrenia, Medical Journal of Chinese People's Health,2008;20(15):1748-9.
355. Chinese source. Ziprasidone and risperidone in the treatment of elderly clinical controlled study of schizophrenia. Medical Journal of Chinese People's Health, 2010;22(10):1214-5.
356. Chinese source. Ziprasidone and quetiapine in the treatment of elderly schizophrenia control analysis, 2010;8(35):297-8.
357. Chinese source. Ziprasidone, and risperidone in the treatment of schizophrenia, 2011;13(06):70-2.
358. Mortimer A. A1281014 a phase IIIb, 12 week, multi-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone versus olanzapine on quality of life in the treatment of schizophrenia and schizoaffective disorder. National Research Register 2001; Vol. 3.
359. Reveley M. MREC/00/1/47 a phase IIIb multicentre randomised double-blind trial of ziprasidone vs olanzapine in schizophrenia. National Research Register 2003; Vol. 2.
360. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
361. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd Edition. American Journal of Psychiatry, 2004:1-114.
362. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
363. Bagnall A, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001945].
364. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
365. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
366. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
367. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The quality of life scale an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388-6.
368. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
369. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Canadian Journal Neurological Sciences 1980;7:233.
370. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
371. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
372. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
373. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2].
374. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
375. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3].
376. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [PUBMED: 11914310].
377. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
378. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf 2006.
379. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
380. Guy 1976. ECDEU assessment for psychopharmacology.. National Institute of Mental Health 1976.
381. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185-94.
382. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
383. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration 2008.
384. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry 2006;63:1079-6.
385. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96. [MEDLINE: 1988325813].
386. Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585-93.
387. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
388. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
389. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
390. Leucht C, Kitzmantel M, Chua L, Leucht S. Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophrenia Bulletin 2008;34:813-5.
391. Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
392. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
393. Marvaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
394. Moher D, Schulz KF, Altman D. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1.
395. Möller HJ. New assessment of atypical antipsychotics [Aktuelle Bewertung neuer/atypischer Neuroleptika]. Nervenarzt 2000;71:329-44.
396. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
397. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
398. Simpson EN, Angus JWF. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
399. Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology. Schizophrenia research 2008;102:1-18.
400. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-55.
401. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92.
402. WHO. New understanding, new hope. The world health report 2001-Mental Health 2001.
403. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007. 2007.
404. Leucht S, Komossa K, Rummel-Kluge C, Hunger H, Schmid C, Schwarz S, Asenjo-Lobos C, Davis JM. A meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166(2):152-63.